Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 457-461

  Shukuya, Takehito ^a,b   Takahashi, Toshiaki ^a   Naito, Tateaki ^a   Kaira, Rieko ^a   Ono, Akira ^a   Nakamura, Yukiko ^a   Tsuya, Asuka ^a   Kenmotsu, Hirotsugu ^a   Murakami, Haruyasu ^a   Harada, Hideyuki ^a   Mitsuya, Koichi ^a   Endo, Masahiro ^a   Nakasu, Yoko ^a   Takahashi, Kazuhisa ^b   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Beyond PD; Brain metastasis; Gefitinib; Non small cell lung cancer; Resistance; Stereotactic radiosurgery; Whole brain irradiation

Indexed keywords

CORTICOSTEROID; ERLOTINIB; GEFITINIB; GLYCEROL; MANNITOL;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; FATIGUE; FEMALE; HEADACHE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEREOTACTIC RADIOTHERAPY; TREATMENT FAILURE; TREATMENT RESPONSE; WHOLE BRAIN RADIOTHERAPY;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 80054766947     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.007     Document Type: Article

References (12)

1. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
2. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
3. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
4. Kosaka T., Yatabe Y., Endoh H., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
5. Lee Y.J., Choi H.J., Kim S.K., et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 2010, 116:1336-1343.
6. Jackman D., Pao W., Riely G.J., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
7. Balak M.N., Gong Y., Riely G.J., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501.
8. Jackman D.M., Holmes A.J., Lindeman N., et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006, 24:4517-4520.
9. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
10. Ricciardi S., Marinis F.D. Multimodality management of non-small cell lung cancer patients with brain metastases. Curr Opin Oncol 2010, 22:86-93.
11. Nussbaum E.S., Djalilian H.R., Cho K.H. Brain metastases histology, multiplicity, surgery, survival. Cancer 1996, 78:1781-1788.
12. Katayama T., Shimizu J., Suda K., et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009, 4:1415-1419.